Paytronix Releases Journey Builder to Enable Self-Service, Ultra-Personalized Messaging Campaigns

NEWTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Paytronix, an Access company, today announced the launch of Journey Builder, an AI-powered campaign automation tool that enables marketers to create sophisticated, multi-touchpoint guest journeys in minutes. Journey Builder is the first release in Paytronix's enhanced Guest Engagement Suite–a unified platform that helps restaurants and convenience stores […]

Arc Trading releases its new AI-driven market-making algorithm

Hong Kong, Oct. 29, 2025 (GLOBE NEWSWIRE) — Arc Trading, a leading crypto market maker, has unveiled its new AI-driven algorithm designed to transform liquidity across digital asset markets. The system introduces predictive execution and cross-exchange synchronization, setting a new benchmark for how liquidity is structured and sustained. A new phase of data-driven liquidity AI

Powder Forms Client Advisory Board to Develop AI Super Agent That Will Double Advisors’ Bandwidth

Los Altos, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — Powder, the fintech company developing generative artificial intelligence (AI) agents to automate critical but time-consuming tasks for wealth managers, today announced the formation of its inaugural client advisory board (CAB). The 10-member board will serve as a consortium of leading industry professionals whose mission is to

CHALLENGED ATHLETES FOUNDATION RAISES OVER $3.5 MILLION THROUGH MILLION DOLLAR CHALLENGE AND SAN DIEGO TRIATHLON CHALLENGE FUELED BY TOYOTA

San Diego, CA, Oct. 29, 2025 (GLOBE NEWSWIRE) — On Sunday, the Challenged Athletes Foundation (CAF) wrapped up a full lineup of fundraising events including the Million Dollar Challenge (MDC) fueled by Toyota, a seven-day California coastal ride raising $1.8 million, the San Diego Triathlon Challenge (SDTC) fueled by Toyota, which raised more than $1.6

Impulse Dynamics(R) Celebrates CMS National Coverage Determination for CCM(R) Therapy

MARLTON, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) — Impulse Dynamics(R), a global medical device company committed to improving the lives of people with heart failure (HF), announced today that the Centers for Medicare and Medicaid Services (CMS) issued a National Coverage Determination (NCD) for CCM(R) therapy. CCM(R) therapy for heart failure (HF) patients is one

SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit with the Schall Law Firm

(NASDAQ:SMLR), LOS ANGELES, Oct. 29, 2025 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. (“Semler” or “the Company”) (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by

The 9/11 Legacy Foundation Named Primary Nonprofit Beneficiary of RunToRemember2977 Initiative

STAMFORD, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) — The 9/11 Legacy Foundation announced today that it will serve as the primary nonprofit beneficiary of RunToRemember2977, a year-long remembrance initiative which formally launched September 11, 2025. The campaign will honor each of the 2,977 innocent lives lost on September 11, 2001, through both physical endurance and

Truveta research published in Radiology Advances introduces new AI model to estimate body composition from chest radiographs

BELLEVUE, Wash., Oct. 29, 2025 (GLOBE NEWSWIRE) — Truveta is proud to announce the publication of its latest peer-reviewed research in Radiology Advances: “XComposition: Multimodal Deep Learning Model to Measure Body Composition Using Chest Radiographs and Clinical Data.” This groundbreaking study demonstrates the power of artificial intelligence to estimate critical body composition measures–such as visceral

FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer

First orphan designation ever granted to a condensate-modulating therapeutic Builds on recent IND opening for DPTX3186, a first-in-class oral condensate modulator targeting the Wnt/B-catenin pathway Provides key regulatory and commercial advantages, including seven years of U.S. market exclusivity upon approval and eligibility for expedited FDA review BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) — Dewpoint Therapeutics,

Scroll to Top